On November 17, 2020, ORIC Pharmaceuticals, Inc., a clinical-stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, announced the closing of its previously announced underwritten public offering of 5,796,000 shares of its common stock, which includes the exercise in full of the underwriters’ option to purchase 756,000 additional shares of its common stock, at a price to the public of $23 per share. The gross proceeds to ORIC from the offering were approximately $133.3 million, before deducting underwriting discounts and commissions and estimated offering expenses.

Wilson Sonsini represented ORIC Pharmaceuticals in the transaction. The team that advised the company includes:

Corporate
Kenneth Clark
Tony Jeffries
Jennifer Knapp
Amanda Urquiza
Grecia Barboza

Employee Benefits & Compensation
Brandon Gantus

Patents and Innovations
Michael Hostetler, Partner
Deborah Smith, Associate

Regulatory
David Hoffmeister, Partner
Eva Yin, Associate

For more information, please see ORIC’s press release.